A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA

Table 8

Change from baseline in WOMAC physical function.

Visits	Curene® 500mg		Placebo
	N=25		N=25
	Mean (SD)	Change from baseline	Mean (SD)	Change from baseline
Baseline (Day 0)	25.12±2.21		24.48±2.71
Visit 2 (Day 7)	23.36±3.05	1.76±1.16	23.76±2.73	0.72±0.98
Visit 3 (Day 15)	21.32±2.85	3.8±1.22	22.32±2.94	2.16±1.31
Visit 4 (Day 30)	17.2±3.65	7.92±2.63	21.44±3.03	3.04±1.79
Visit 5 (Day 60)	12.04±3.12	13.08±2.81	20.04±3.77	4.44±2.63

Statistically significant (P <0.05) within group; statistically significant (P <0.05) between group.
Within group analysis by Pair t-test and between group analysis by repeated measures ANCOVA.